Clinical trial
Apremilast for the Treatment of Refractory Erythema Multiforme
NCT05875714 is registered in ClinicalTrials.gov with Robert Micheletti as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Apremilast for the Treatment of Refractory Erythema Multiforme
- Lead sponsor
- Robert Micheletti
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- January 13, 2022
- Completion date
- December 31, 2024
- Enrollment
- 6 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.